Table 1. Demographic and clinical characteristics of patients treated with afatinib (n=133).
| Demographic and clinical characteristics | Values |
|---|---|
| Age (years), mean ± SD | 64.1±10.5 |
| Gender, n (%) | |
| Female | 78 (58.6) |
| Male | 55 (41.4) |
| Ethnicity, n (%) | |
| Malay | 44 (33.1) |
| Chinese | 80 (60.2) |
| Indian | 1 (0.8) |
| Others† | 8 (6.0) |
| Smoking history, n (%) | |
| Never smoker | 111 (83.5) |
| Previous or current smoker | 22 (16.5) |
| ECOG performance status at diagnosis, n (%) | |
| ECOG 0–1 | 22 (16.5) |
| 0 | 0 |
| 1 | 22 (16.5) |
| ECOG 2–4 | 111 (83.5) |
| 2 | 64 (48.1) |
| 3 | 25 (18.8) |
| 4 | 22 (16.6) |
| Comorbidities n (%) | |
| No | 84 (63.2) |
| Yes | 49 (36.8) |
| Diabetes mellitus | 35 (26.3) |
| Hypertension | 19 (14.3) |
| Ischemic heart disease | 5 (3.8) |
| Stroke | 4 (3.0) |
| Chronic kidney disease | 1 (0.8) |
| Others‡ | 21 (15.8) |
| Tumor histology, n (%) | |
| Adenocarcinoma | 126 (94.7) |
| Squamous cell carcinoma | 4 (3.0) |
| Others§ | 3 (2.3) |
| Tumor stage, n (%) | |
| IIIC | 10 (7.5) |
| IVA | 70 (52.6) |
| IVB | 53 (39.8) |
| Symptomatic baseline brain metastases, n (%) | |
| No | 87 (65.4) |
| Yes | 46 (34.6) |
| EGFR mutation subtype, n (%) | |
| Exon 19 deletion | 81 (60.9) |
| Exon 21 L858R point mutation | 31 (23.3) |
| Resistant mutation | 4 (3.0) |
| Exon 20 insertion | 3 (2.2) |
| Exon 20 insertion and Exon 20 S768I | 1 (0.8) |
| Rare or compound mutations | 17 (12.8) |
| Exon 18 G719X | 6 (4.5) |
| Exon 21 L861Q | 6 (4.5) |
| Exon 18 G719X and exon 20 S768I | 5 (3.8) |
†, others: native from Sabah and Sarawak; ‡, others: 10 hyperlipidemia, 4 hyperparathyroid, 2 gouts, 2 orthopedic problem, 1 benign prostatic hyperplasia, 1 asthma, 1 hepatitis B infection; §, others: 1 adenosquamous, 1 favor adenocarcinoma, 1 adenocarcinoma not otherwise specified. SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.